Oral immunization with a novel lipid-based adjuvant protects against genital Chlamydia infection

Vaccine

Volumn 28, Issue 7, 2010, Pages 1668-1672

  Hickey, Danica K ^a,b   Aldwell, Frank E ^c   Beagley, Kenneth W ^d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Adjuvant; Chlamydia; Lipid; Oral immunization

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; CHOLERA TOXIN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; LIPID C; MAJOR OUTER MEMBRANE PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL WARFARE; CHLAMYDIASIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; FEMALE; GENITAL TRACT INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; CHOLERA TOXIN; FEMALE; GENITAL DISEASES, FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES; TRIGLYCERIDES; VAGINA;

EID: 75249096182     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.010     Document Type: Article

References (31)

1. Beagley K.W., and Timms P. Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development. J Reprod Immunol 48 1 (2000) 47-68
2. Westrom L., and Mardh P.A. Chlamydial salpingitis. Br Med Bull 39 April (2) (1983) 145-150
3. Ho J.L., He S., Hu A., Geng J., Basile F.G., Almeida M.G., et al. Neutrophils from human immunodeficiency virus (HIV)-seronegative donors induce HIV replication from HIV-infected patients' mononuclear cells and cell lines: an in vitro model of HIV transmission facilitated by Chlamydia trachomatis. J Exp Med 181 April (4) (1995) 1493-1505
4. Kaul R., Nagelkerke N.J., Kimani J., Ngugi E., Bwayo J.J., Macdonald K.S., et al. Prevalent Herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J Infect Dis 196 December (11) (2007) 1692-1697
5. Stamm W.E. Rationale for a vaccine. In: Woodall J.P. (Ed). Proceedings of the Chlamydia vaccine development colloquium; 2004 (2004), The Albert B. Sabin Vaccine Institute, Alexandia, Virginia 15-18
6. Weiner H.L. Oral tolerance, an active immunologic process mediated by multiple mechanisms. J Clin Invest 106 October (8) (2000) 935-937
7. Williams N.A., Hirst T.R., and Nashar T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol Today 20 2 (1999) 95-101 [Review] [63 refs]
8. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 9 (2000) 4778-4782
9. Aldwell F.E., Tucker I.G., de Lisle G.W., and Buddle B.M. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect Immun 71 1 (2003) 101-108
10. Nol P., Palmer M.V., Waters W.R., Aldwell F.E., Buddle B.M., Triantis J.M., et al. Efficacy of oral and parenteral routes of Mycobacterium bovis Bacille Calmette-Guerin vaccination against experimental bovine tuberculosis in white-tailed deer (Odocoileus virginianus): a feasibility study. J Wildl Dis 44 April (2) (2008) 247-259
11. Clark S., Cross M.L., Nadian A., Vipond J., Court P., Williams A., et al. Oral vaccination of guinea pigs with Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis. Infect Immun 76 8 (2008) 3771-3776
12. Aldwell F.E., Keen D.L., Parlane N.A., Skinner M.A., de Lisle G.W., and Buddle B.M. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums. Vaccine 22 December (1) (2003) 70-76
13. Berry L.J., Hickey D.K., Skelding K.A., Bao S., Rendina A.M., Hansbro P.M., et al. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72 February (2) (2004) 1019-1028
14. Barker C.J., Beagley K.W., Hafner L.M., and Timms P. In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB. Vaccine 26 March (10) (2008) 1285-1296
15. Carey A.J., Cunningham K.A., Hafner L.M., Timms P., and Beagley K.W. Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice. Immunol Cell Biol 87 May-June (4) (2009) 337-343
16. Challacombe S.J., Rahman D., and O'Hagan D.T. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 15 February (2) (1997) 169-175
17. Briese V., Pohl W.D., Noack K., Tischner H., and Waldman R.H. Influenza specific antibodies in the female genital tract of mice after oral administration of live influenza vaccine. Arch Gynecol 240 3 (1987) 153-157
18. Zhang X., Lou Y.H., Koopman M., Doggett T., Tung K.S., and Curtiss Rr. Antibody responses and infertility in mice following oral immunization with attenuated Salmonella typhimurium expressing recombinant murine ZP3 [published erratum appears in Biol Reprod 1997 Apr;56(4):1069]. Biol Reprod 56 1 (1997) 33-41
19. Whittum-Hudson J.A., An L.L., Saltzman W.M., Prendergast R.A., and MacDonald A.B. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat Med 2 10 (1996) 1116-1121
20. Grayston J.T., and Wang S.P. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 5 2 (1978) 73-77 [Review] [19 refs]
21. Aldwell F.E., Cross M.L., Fitzpatrick C.E., Lambeth M.R., de Lisle G.W., and Buddle B.M. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine 24 March (12) (2006) 2071-2078
22. Armand M. Lipases and lipolysis in the human digestive tract: where do we stand?. Curr Opin Clin Nutr Metab Care 10 March (2) (2007) 156-164
23. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2 4 (2001) 361-367
24. Horejsi V. The roles of membrane microdomains (rafts) in T cell activation. Immunol Rev 191 February (2003) 148-164
25. Dykstra M., Cherukuri A., Sohn H.W., Tzeng S.J., and Pierce S.K. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 21 (2003) 457-481
26. Anderson H.A., Hiltbold E.M., and Roche P.A. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol 1 August (2) (2000) 156-162
27. Mahoney E.M., Hamill A.L., Scott W.A., and Cohn Z.A. Response of endocytosis to altered fatty acyl composition of macrophage phospholipids. Proc Natl Acad Sci USA 74 November (11) (1977) 4895-4899
28. Weatherill A.R., Lee J.Y., Zhao L., Lemay D.G., Youn H.S., and Hwang D.H. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR4. J Immunol 174 May (9) (2005) 5390-5397
29. Schweitzer S.C., Reding A.M., Patton H.M., Sullivan T.P., Stubbs C.E., Villalobos-Menuey E., et al. Endogenous versus exogenous fatty acid availability affects lysosomal acidity and MHC class II expression. J Lipid Res 47 November (11) (2006) 2525-2537
30. Calder P.C., Bond J.A., and Newsholme E.A. Fatty acid inhibition of concanavalin A-stimulated lymphocyte proliferation. Biochem Soc Trans 17 December (6) (1989) 1042-1043
31. Calder P.C., Bond J.A., and Newsholme E.A. Fatty acid inhibition of lipopolysaccharide-stimulated B lymphocyte proliferation. Biochem Soc Trans 18 October (5) (1990) 904-905